Company News: Johnson & Johnson, PriCara, Novartis and Merck KGaA

Share this article:
Johnson & Johnson's PriCara launched PrescribeResponsibly.com, a website for healthcare professionals on appropriate and responsible prescribing of opioid analgesics including case studies, sections about the role of genetics in pain and response to opioid drugs and info about the importance of considering these factors in prescribing. PriCara makes Duragesic, Ultram ER and Nucynta.
 
Three January New England Journal of Medicine studies showed that oral medications for multiple sclerosis from Novartis and Merck KGaA reduce relapse and worsening of the neurological disease. Patients who took the drugs had higher rates of infections, though. Novartis has applied for US approval of FTY720, while Merck KGaA's Merck Serono unit must resubmit its application for cladrabine after receiving an FDA refuse-to-file letter.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.